Pfizer revenue misses as breast cancer drug sales disappoint

(Reuters) - Pfizer Inc's quarterly revenue missed analysts' estimates on Tuesday, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.

Pfizer revenue misses as breast cancer drug sales disappoint
Read More


Bagikan Berita Ini